Research programme: PPAR agonists - Merck & Co

Drug Profile

Research programme: PPAR agonists - Merck & Co

Latest Information Update: 30 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Benzimidazoles; Benzopyrans; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Type 2 diabetes mellitus
  • Discontinued Hyperlipidaemia

Most Recent Events

  • 30 Aug 2011 Discontinued - Preclinical for Hyperlipidaemia in USA (PO)
  • 30 Aug 2011 No development reported for Type-2 diabetes mellitus in USA (PO)
  • 10 Apr 2008 Research phase development is ongoing for Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top